Skip to main content

Roche and CombiMatrix Strike Deal to Develop and Market Biochip Technology

NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.

The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.

Financial details of the agreement were not disclosed.

“This unique platform will be useful for multiple applications, including gene expression studies, single nucleotide polymorphism analysis, disease classification, pathway identification, and toxicology studies, Susanne Raehs, head of Roche Applied Science, said in a statement.

Acacia Research is the majority owner of Snoqualmie, Wash.-based CombiMatrix, which uses semiconductor technology to develop customizable microarrays. CombiMatrix remains registered for an initial public offering filed in November.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.